KNOWLEDGE BANK

Interviews

Exploring New Molecular Targets for Anti-cancer Therapy

Clinical Professor, Department of Medicine, University of British Columbia
Amil Shah is Clinical Professor of Medicine at the University of British Columbia His practice focusses on gastrointestinal and lung cancers Among his administrativeacademic roles he chaired the Gastrointestinal Tumour Group at BC Cancer and served as Associate Dean of the VancouverFraser Medical Program at UBC His research interest is the molecular pathogenesis of cancer

Articles

The Use of AI in Pharmacovigilance

Regulatory authorities RAs across the world are showing increased interest in the use and applications of artificial intelligence AI in pharmacovigilance PV At the same time these new cognitive technologies have generated concerns in the regulatory space public health and the life sciences industry RAs from different regions are focusing their efforts on developing standards and good practices for...

Research Insights

Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection

Antiretroviral therapy ART for HIV infection is lifelong Stopping therapy typically leads to the reignition of infection and progressive disease In a major breakthrough recent studies have shown that early initiation of ART can lead to sustained posttreatment control of viremia

Case Studies

Long-term Use Of Statins And Risk Of Renal Cell Carcinoma: A Population-based Case–control Study

Abstract Background Use of statins has been suggested to protect against renal cell carcinoma RCC however studies have typically been underpowered and the results are conflicting Objective To determine whether the use of statins is associated with a reduced risk of RCC usin

Techno Trends

Researchers Develop DNA-encoded PCSK9 Inhibitors to Regulate Cholesterol Levels in Bloodstream

The Wistar Institute researchers have developed novel synthetic DNAencoded Monoclonal Antibodies DMAbs directed against PCSK a protein key to regulating cholesterol levels in the bloodstream A preclinical study showed a significant cholesterol decrease helping for the development of this approach as a simple less frequent and costeffective therapy Elevated LowDe...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Incipient Biopharmaceutical Claims of Milk Derived Exosomes

Rakesh Kumar Tekade

Rakesh K. Tekade is a formulation researcher with of teaching and research experience. He has an explicit experience of over 10 years in teaching various modules for Ph.D, Masters & Bachelors students (@ Universities based in USA, UK, Malaysia, & India). He currently serving as Associate Professor at NIPER-Ahmedabad (An Institute of National Importance Government of India). Prior to this, Dr. Tekade was faculty at International Medical University, Kuala Lumpur, Malaysia. He took his postdoctoral trainings from UT Southwestern Medical Centre, Dallas, Texas, USA and University of Hawaii, Hilo, Hawaii, USA. He is a recipient of Commonwealth Fellowship at University of Central Lancashire, Preston, UK. Recently, Dr Tekade has been listed as Top 2% researcher in the field of Pharmacy and Pharmacology, by Stanford University, USA.

 

Nupur Vasdev

Nupur Vasdev is currently pursuing her PhD in the department of pharmaceutics from NIPER-Ahmedabad. She has completed M.S (Pharm.) in pharmaceutics from NIPER-Raebareli. She is currently working on targeted nano particulate drug delivery for obesity and cancer. Her research focus also includes surface modified exosome drug delivery for cancer and obesity.

 

Manisha Choudhary

Manisha Choudhary is currently pursuing her M.S. (Pharm) in Pharmaceutics at NIPER-Ahmedabad, India. She is currently working on aptamer decorated nanomaterials for improving the targeting. Her work majorly focuses on the improvement of the stability, targeting and robustness of aptamer conjugated nanomaterials for cancer treatment. Her work also focusses on the extraction of natural derived exosomes.

 

Suryanarayana Polaka

Suryanarayana Polaka is currently pursuing his PhD at NIPER-Ahmedabad, India. He is working in targeted drug delivery systems for the treatment of rheumatoid arthritis and wound healing. He also works on exosome mediated drug delivery. He co-authored 10 peer-reviewed publications in international journals, contributed > 7 international reference book chapters.

 

Kiran Kalia

Professor Kiran Kalia is a currently serving as Director and Professor at NIPER-Ahmedabad. Her work basically focused on the Proteomic markers for diabetic nephropathy, diabetic retinopathy and metal toxicity studies. Recently she started exploring the exosomes mediated drug delivery for delivering the genes for treating various ailments like cancer, wounds and diabetic nephropathy.

 

2

The Exosome Manufacturing Gap

Dr Deepika Arora

Dr Deepika Arora is an accomplished professional with expertise in project management, process improvement, and operational excellence. She brings strong scientific expertise and experience in prolific biologics, contributing to innovation and quality-driven outcomes. With a commitment to continuous learning, she has led cross-functional initiatives across diverse industries and writes on leadership, strategy, and professional development.

Aditya Banerjee

Aditya Banerjee is a senior scientist specialising in stem cell biology, regenerative medicine, and translational research. His work focuses on GMP-compliant cell therapy manufacturing, exosome research, and quality systems. Passionate about advancing scientific innovation, he writes on emerging biotechnologies, laboratory excellence, and their translation into meaningful clinical applications.

3

Boosting NICU Safety

Norhan Attia

Norhan Attia, clinical pharmacist with five years' experience at Assiut University Hospital, Egypt, specialising in Neonatal Intensive Care. Expert in medication reviews, IV admixtures, and optimising pharmacotherapy outcomes. Currently a dedicated teaching assistant, focusing on pharmaceutical education and enhancing medication safety in NICU settings.

4

Integrated by Design

Venkat Reddy Sunkara

Venkat Reddy Sunkara is global head of Regulatory CMC at ICON. He has extensive expertise in managing Chemistry, Manufacturing, and Controls (CMC) aspects of regulatory submissions and post market compliance, supporting clients in achieving and maintaining adherence to global regulatory requirements. He brings over 20 years of pharmaceutical industry experience, including more than 10 years in CMO/CRO environments specializing in Regulatory CMC. 

5

3D Printing

Stéphane Roulon

Stéphane Roulon is a pharmaceutical entrepreneur with over ten years of experience in developing 3D printing technologies for drug manufacturing. He is the CEO of MB Therapeutics, a pharmaceutical establishment specializing in personalized medicines produced using advanced 3D printing solutions to support the future of precision medicine.

press releasesRead more...

Takeda and Zuellig Pharma Announce Strategic Regional Collaboration to Expand Patient Access to Takeda's Innovative Medicines Across Southeast Asia

Takeda and Zuellig Pharma today announced a strategic regional collaboration to enhance sustainable patient access to innovative medicines and healthcare solutions across Malaysia Indonesia and the Philippines Effective December the collaboration

Delonix Bioworks and A*STAR Infectious Diseases Labs Announce Research Collaboration to Advance Novel Engineered OMV Vaccine Candidates Against Klebsiella pneumoniae

Delonix Bioworks a clinicalstage biotechnology company pioneering nextgeneration outer membrane vesicle OMV vaccines today announced that it has entered into a Research Collaboration Agreement with ASTAR Infectious Diseases

Lonza and CMS Sign License Agreement for NeuroPortal™ TfR1 Blood-Brain Barrier Technology

Lonza and China Medical System Holdings Limited CMS announced today a global exclusive license agreement for the use of Lonzas NeuroPortal transferrin receptor TfR bloodbrain barrier BBB technology in up to two products targeting

Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery

AIdriven protein design is accelerating the discovery of novel protein binders but experimental validation remains essential to determine whether computational designs translate into meaningful target interactions To bridge this gap Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in r...

Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer

Innovent Biologics Inc Innovent HKEX a worldclass biopharmaceutical company that develops manufactures and commercializes highquality medicines for the treatment of oncologic autoimmune cardiovascular and metabolic

Biocon Limited BSE NSE BIOCON an innovationled global biopharmaceutical company today announced that the US Food and Drug Administration FDA has approved Pebrilzo pertuzumabqcay a biosimilar of the reference

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

OXB Partners with Aura Biosciences for Drug Manufacturing

OXB has confirmed a manufacturing and supply partnership with Aura Biosciences

GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer

GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC

Erasca Enters into Collaboration with Bristol Myers Squibb to Evaluate Pancreatic Cancer Therapy

Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers to evaluate the combination of ERAS and navlimetostat BMS an investigational PRMT inhibitor in patients with pancreatic cancer

OBI Pharma and Novartis Partner to Develop Next-Generation ADCs for Cancer Treatment

OBI Pharma has entered into a collaboration and licensing agreement with Novartis to develop nextgeneration antibodydrug conjugates ADCs using novel payloads and OBIs proprietary technology platforms

Merck to Acquire Rapid Micro Biosystems to Strengthen Automation in Pharmaceutical Quality Control

Merck has signed a definitive agreement to acquire Rapid Micro Biosystems a USbased provider of automated microbial qualitycontrol testing solutions for pharmaceutical manufacturing

Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer

Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer